Why did ITRM's EPS remain stagnant in recent quarters?

Iterum Therapeutics' (ITRM) earnings per share (EPS) has shown variability but no clear trend of stabilization in recent quarters. The company's EPS was -23 cents for Q2 2024, -81 cents for Q4 2023, and -38 cents for Q1 2024. The fluctuation in EPS can be attributed to several factors:

1. **Lack of Revenue**: Iterum Therapeutics has not reported any revenue in several quarters, which significantly impacts the company's net income and, consequently, its EPS. The absence of revenue contributes to the negative EPS figures.
2. **Financial Challenges**: The company's financial challenges, as indicated by an EBITDA of -$18.4 million in the last twelve months, suggest that Iterum Therapeutics is struggling to generate profitability. This financial instability can lead to fluctuations in EPS due to the variability in net income.
3. **Industry Performance**: The company's performance compared to its industry peers shows that Iterum Therapeutics has outperformed its overall industry in earnings estimates but has not met sales estimates. This mixed performance could contribute to the observed fluctuations in EPS.

In summary, the stagnation in Iterum Therapeutics' EPS in recent quarters can be attributed to the lack of revenue, financial challenges, and mixed performance compared to industry peers.